RIVANNA Medical

RIVANNA Medical develops AI-automated clinical decision support platforms for spinal needle intervention guidance and musculoskeletal diagnostics at the point of care. The company's proprietary technology combines deep learning algorithms trained on proprietary clinical datasets with advanced 3D ultrasound transducer technology to reduce operator variability and accelerate clinical decision-making in emergency medicine and anesthesia applications. Core product offerings include the Accuro 3S Needle Guide Kit (FDA 510(k) cleared as of December 2025) for neuraxial anesthesia procedures, and an AI-powered fracture triage platform for emergency department point-of-care imaging. Both products leverage RIVANNA's unified AI imaging architecture, which integrates SafeTrack™ needle tracking technology, Dual-Array™ multi-angle probe technology, and 3D volumetric imaging capabilities. The platforms feature portable bedside deployment, automated acquisition with minimal training dependency, real-time needle tip positioning overlays, and seamless EMR and DICOM integration with cloud connectivity for fleet analytics. The company addresses critical healthcare delivery gaps: ~70% of extremity fracture cases in emergency departments are rule-outs, yet patients wait hours for radiology confirmation; neuraxial anesthesia procedures relying on landmark palpation exhibit 38% first-attempt failure rates in challenging anatomies. RIVANNA's platforms target a combined total addressable market of $3.4B+ across neuraxial guidance ($1.9B) and fracture care ($1.5B). Validation includes NIH federal support, 8 clinical sites with 1,200+ enrolled subjects, peer-reviewed publication in Journal of Emergency Medicine (2026), and $3 million CDMRP grant award for military-optimized ultrasound guidance systems. The company holds 48 global patents and patents pending. Regulatory pathway includes FDA 510(k) clearance for Accuro 3S consumables, with SafeTrack™ needle tracking and fracture platform submissions pending. ICD-10-PCS coding is pending; CPT pathway validation is underway with major medical societies.